Design and Setting
This prospective observational study was approved by the Institutional Review Board of Nara Medical University (Kashihara, Nara, Japan; Approval No. 2127) and registered with the UMIN Clinical Trials Registry (UMIN 0035832). Written informed consent was obtained from all patients. This manuscript adheres to the applicable Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Women aged ≥ 20 years who underwent cesarean delivery between 0700 and 2000 hours under spinal anesthesia between April 2019 and March 2020 were screened, including both elective and non-elective cases, irrespective of the gestational age. The exclusion criteria were as follows: patients with psychiatric or neuromuscular diseases; those who did not provide written informed consent; those who received anesthesia other than single-shot spinal anesthesia (multiple administrations of spinal anesthesia, epidural anesthesia, combined spinal-epidural anesthesia, and general anesthesia), those who underwent cesarean delivery following epidural labor. Women who required additional sedatives and analgesics intraoperatively, those who received oxygen administration postoperatively, those with missing data regarding demographics and respiratory monitoring, and those with respiratory monitoring within 6 hours postoperatively were excluded from data analysis[10].
In our institution, spinal anesthesia was administered with 2–2.5 ml of hyperbaric bupivacaine (0.5%), 10 μg of fentanyl, and 100 μg of morphine with the patient in the lateral position after attaching the standard anesthesia monitors. Intraoperative patient management—including blood pressure management and additional sedation and analgesia—was at the discretion of the anesthesiologist. After cesarean delivery, patients were discharged from the operating room with an adhesive acoustic respiration sensor (RAS-125™ or RAS-125™ rev C, Masimo) and an oximetry sensor (LNCS Adtx, Masimo) placed on the neck and finger, respectively, which were connected to an Acoustic Respiration Rate (RRa) pulse oximeter to monitor and regularly record RR and oxygen saturation (SpO2). Patients were continuously monitored with the RRa device until initiation of ambulation. The RRa and SpO2 were calculated as 10-s moving average every 2 s and 8-s moving average every 1 s, respectively, and stored in the internal memory. The pulse oximetry data were temporarily and automatically stored in the internal memory with a 2-s resolution. After the monitoring device was detached, one of the researchers transferred the data to a storage device using TrendCom v3460 (Masimo) and saved the file. The nurses observed the patients’ vital signs including their respiratory rate, postoperative pain, opioid-related adverse events (postoperative nausea, vomiting, and pruritus) every 30 minutes for up to 2 hours postoperatively and every hour for 2–24 hours postoperatively according to our institutional protocol. For postoperative pain reduction, intravenous acetaminophen (1 g) was administered four times every 6 hours; upon request for additional analgesia, pentazocine and/or flurbiprofen was administered at the discretion of the obstetrician.
Collected data
Maternal demographic data, including the age, current body mass index, gestational age, presence of hypertension including hypertensive disorder of pregnancy, and presence of diabetes mellitus were collected. The Berlin questionnaire was used to screen for obstructive sleep apnea syndrome preoperatively; it consists of the following three categories: snoring (category 1), sleepiness and fatigue on awakening (category 2), and obesity (body mass index > 30 kg/m2) and hypertension (category 3). Each question is scored on a scale of 0–2. The scores are summed for each category; ≥ 2 points in categories 1 and 2 and ≥ 1 point in category 3 were considered positive, and ≥ 2 positive categories were representative of high risk of sleep-disordered breathing [12]. Additionally, elective or emergency surgery and administration of magnesium and ritodrine were retrieved from the electronic medical records.
Outcomes
The primary outcome of interest was the median rate of cumulative sustained bradypnea time (total sustained bradypnea time/total monitoring time) and its related factors. The secondary outcomes included the following: (1) median time to first sustained bradypnea after intrathecal morphine administration; (2) incidence of sustained and immediate bradypnea and its related factors; (3) incidence of sustained and immediate hypoxemia and related factors; and (4) occurrence of clinically relevant episode of respiratory depression, which was defined as that which required naloxone or calling the rapid response team. The following definitions were used in this study with reference previous study [13]: sustained bradypnea: respiratory rate < 8 bpm lasting at least 25 s; immediate bradypnea: respiratory rate < 8 bpm lasting at least 15 s; sustained hypoxemia: SpO2 < 92% lasting at least 25 s; and immediate hypoxemia: SpO2 < 92% lasting at least 15 s.
Statistical analysis
Continuous variables are presented as mean (standard deviation) and categorical variables as numbers (present). Although body mass index is a continuous variable, it was presented as a categorical variable based on the cutoff in the Berlin questionnaire asks of 30 kg/m2. To compare the patient demographic data, univariate analysis was performed using Fisher’s exact test or Mann–Whitney U test, as appropriate. Multiple regression analysis was used to assess the variables related to the cumulative sustained bradypnea time rate, in which all explanatory factors, except for body mass index and hypertension status, were included in the Berlin Questionnaire. For evaluation of the secondary outcomes, each incidence was expressed as a percentage and each related factor was explored using multiple logistic regression analysis in which the calibration of the model was tested using the Hosmer–Lemeshow test and the area under the receiver operating characteristic curve was computed as a descriptive tool for measuring the model bias. All data were analyzed using SPSS v22.0 (IBM Inc., Armonk, NY, USA) and P<0.05 was considered statistically significant.
Considering the seven covariates included in the multiple regression analysis, the minimum required sample size, which was calculated using G*power v3.1 (Faul, Erdfelder, Lang, & Buchner, 2007) with the requirements of type I (α) error, power (1-β), and effect size (f2) of 0.05, 0.95, and 0.15 (medium effect size), respectively, was found to be 153 patients. After accounting for a potential dropout rate of 30%, we decided to enroll 219 patients who met the inclusion criteria.